Iovance Biotherapeutics: Rising Amtagvi demand secures higher target for 2026 - 10% stock jump leads the stock to a 52-week high!

Iovance Biotherapeutics raises its revenue forecast for 2026 to $410 to $420 million. The increase is driven by rising US demand for Amtagvi and Proleukin. Shorter production times and over 110 treatment centers support growth. Cell therapies for solid tumors reach clinical practice The business model of Iovance (IOVA) is based on tumor-infiltrating lymphocytes (TIL). The company extracts the patient's own immune cells, multiplies them in the lab, and then reinfuses them back into the patient. With Amtagvi, Iovance has the first approved...